Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy --
Covered in this story
What has happened since
- Provident Financial Services Inc is down 2.5% since this was published, 41 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $PFS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Provident Financial Services Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.